"We recently completed the phase 1 portion of our Acclaim-1 clinical trial evaluating Reqorsa in combination with Tagrisso for NSCLC," Mark Berger, MD, the chief medical officer of Genprex and study director, said in a statement issued to CGTLive ™. "We also recently reported positive preliminary clinical data from this trial, which showed that Reqorsa was generally well tolerated, and there were no dose-limiting toxicities. While the phase 1 portion of the clinical trial is designed primarily to assess safety, promising efficacy results were also observed, as there were several patients who were progressing on their previous therapy [who] experienced long periods of response or stable disease. We look forward to treating patients in the upcoming phase 2 portion of our study soon."